AgomAb Therapeutics (NASDAQ:AGMB) Stock Rating Lowered by Wall Street Zen

AgomAb Therapeutics (NASDAQ:AGMB) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Several other equities analysts have also commented on the company. HC Wainwright began coverage on AgomAb Therapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $35.00 target price for the company. B. Riley Financial began coverage on AgomAb Therapeutics in a research note on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $33.00.

AgomAb Therapeutics Price Performance

AGMB stock opened at $13.22 on Friday. AgomAb Therapeutics has a one year low of $8.75 and a one year high of $17.82. The stock has a 50 day moving average price of $12.52.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. As a group, sell-side analysts expect that AgomAb Therapeutics will post -1.77 EPS for the current year.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.